Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Hao Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7191-5118; OpenAlex author ID A5100348489. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. Co-author DOI 10.1016/j.cell.2024.09.024↗
  2. The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis. Co-author DOI 10.1038/s41388-023-02647-0↗
  3. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  4. Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis Co-author DOI 10.21203/rs.3.rs-307202/v1↗
  5. Angiogenesis in pancreatic cancer: current research status and clinical implications. Co-author DOI 10.1007/s10456-018-9645-2↗
  6. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Co-author DOI 10.7150/jca.32072↗
  7. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  8. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-018-6737-6↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaxiang Xu · 6 shared papers, 2018–2023 · strength 0.67
  2. Xianjun Yu · 5 shared papers, 2018–2022 · strength 0.49
  3. Liang Liu · 5 shared papers, 2018–2022 · strength 0.48
  4. Shirong Zhang · 3 shared papers, 2018–2023 · strength 0.37
  5. Wei Jin · 3 shared papers, 2018–2023 · strength 0.34
  6. Liang Liu · 2 shared papers, 2021–2023 · strength 0.30
  7. Xian-Jun Yu · 2 shared papers, 2018–2023 · strength 0.29
  8. Wen-Quan Wang · 3 shared papers, 2018–2019 · strength 0.28
  9. Shi-Rong Zhang · 3 shared papers, 2018–2019 · strength 0.28
  10. Chuntao Wu · 3 shared papers, 2018–2019 · strength 0.24
  11. Tianjiao Li · 2 shared papers, 2021–2022 · strength 0.24
  12. Long‐Yun Ye · 2 shared papers, 2021–2022 · strength 0.24
  13. Shuo Li · 2 shared papers, 2018–2019 · strength 0.16
  14. David Tsai Ting · 1 shared paper, 2024 · strength 0.15
  15. Benjamin D. Greenbaum · 1 shared paper, 2024 · strength 0.15
  16. Siyu Sun · 1 shared paper, 2024 · strength 0.15
  17. Eunae You · 1 shared paper, 2024 · strength 0.15
  18. Rebecca L. Porter · 1 shared paper, 2024 · strength 0.15
  19. Vikram Deshpande · 1 shared paper, 2024 · strength 0.15
  20. Andrew Scott Liss · 1 shared paper, 2024 · strength 0.15
  21. Tae Kyoung Kim · 1 shared paper, 2024 · strength 0.15
  22. Saimeng Shi · 1 shared paper, 2022 · strength 0.13
  23. Zhiwen Xiao · 1 shared paper, 2022 · strength 0.13
  24. Qinglin Fei · 1 shared paper, 2022 · strength 0.13
  25. Weiding Wu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.